MENA has historically punched below its weight in global research. A 2011 industry review found the region accounted for just 5.5% of the world's registered trials, despite housing populations with high rates of diabetes, cardiovascular disease, and genetic disorders MENA: The Dawn of a New Era. A broader 2019 roadmap covering the Middle East and North Africa found similarly thin representation — just 6% of worldwide trials across 68 countries and 1.6 billion people.
This article breaks down the region's fastest-growing markets, the regulatory pathways sponsors need to navigate, and the practical challenges that trip up multi-country studies.
Key Takeaways
- Large, treatment-naive, genetically diverse MENA populations support strong Phase II–III recruitment
- Saudi Arabia, UAE, Egypt, Jordan, and Qatar lead regional regulatory activity
- Approval pathways, language rules, and IMP procedures differ by country and need tailored plans
- Local regulatory expertise reduces study start-up delays and compliance risk
Why MENA Is Gaining Momentum in Global Clinical Research
Disease burden in the region is climbing fast. According to the IDF Diabetes Atlas 2025, 84.7 million adults in MENA were living with diabetes as of 2024, a regional prevalence of 17.6%. Cases are projected to nearly double to 163 million by 2050. That kind of prevalence creates real demand for region-specific trial data rather than imported findings from Western populations.
Government initiatives are reinforcing this shift:
- Saudi Vision 2030: Health Sector Transformation Program expands modern facilities, digital health, and private-sector investment
- SEHA Virtual Hospital: Connected more than 150 hospitals across specialized services
- We the UAE 2031: Targets a top-10 global position for healthcare quality
Sponsors are also drawn by potentially lower operating costs and faster patient identification in treatment-naive populations. These remain qualitative advantages rather than guaranteed savings. Every market still needs its own feasibility work.
Key MENA Markets for Clinical Trial Planning
Saudi Arabia
Saudi Arabia is the largest pharmaceutical market in the Arab region, and its regulatory body, the Saudi FDA (SFDA), has matured considerably. SFDA's clinical trial guidance requires:
- A local legal representative in-country
- A separate import license for investigational products
- Registration with SCTR (note: registration is not the same as approval)
SFDA also publishes response-clock benchmarks after a complete submission:
Trial Category SFDA Response Clock Phase IV 10 working days Bioequivalence 15 working days Phase III 30 working days Phase II 40 working days Phase I / biologics 60 working days Alongside those clocks, the Saudi NIH runs a clinical trial funding call that requires GCP certification, IRB approval, and SFDA sign-off, with terms up to 36 months and funding up to SAR 4,000,000.
United Arab Emirates
The UAE's Department of Health issued formal clinical trial guidelines in January 2020, applying to DoH-licensed entities using unapproved investigational products. Requirements include:
- Compliance with GCP, JCI standards, and ISO 14155 for devices
- Research ethics committees with at least five members, including one nonscientific and one independent member
- SUSAR reporting within 7 days for fatal/life-threatening events, 15 days for others Dubai and Abu Dhabi have become regional hubs largely because of hospital infrastructure — institutions like American Hospital Dubai and Cleveland Clinic Abu Dhabi both hold JCI accreditation, a signal of international-standard site readiness.
Egypt
Egypt combines a large treatment-naive population with a regulatory framework that's steadily modernized. ICH-GCP was formally adopted in 2006 for biologics, then extended to pharmaceuticals in 2016. The Clinical Medical Research Law (214/2020) now places institutional review boards under a Supreme Council affiliated with the Prime Minister's office, requiring both EDA and Council approval before research begins. Egypt's hepatitis C history also illustrates the region's targeted-study potential. National screening prevalence dropped from roughly 10% to 0.38% after a campaign that tested more than 60 million people and treated over 4.1 million (WHO EMRO, 2023). Few markets can match that scale of disease surveillance infrastructure.
Qatar and Jordan
Qatar's trial activity picked up around 2020, driven partly by COVID-related research. A 2022 GCC-wide analysis found:
- 10.3% of all GCC trials ran in Qatar
- Highest per-capita trial rate in the bloc at 42.78 trials per million population Jordan's national regulator, the Jordan FDA, operates as an independent competent authority overseeing medicine safety and efficacy, with its own National Clinical Trials Registry. Both countries remain smaller markets, but they're increasingly credible for niche indications and rare disease studies where patient registries and government support matter more than sheer population size.
Navigating Regulatory Pathways Across the Region
Most MENA countries still require sequential approval (ethics committee sign-off first, then regulatory authority review) rather than the parallel submission models common in the US or EU. Planning timelines around this sequence, rather than assuming simultaneous review, avoids a common sponsor mistake.
Language and logistics add further complexity:
- Arabic translation is mandatory for patient-facing documents across the region
- French is additionally required in North African countries
- IMP import/export rules vary by jurisdiction, with some countries requiring separate authority approval to export biological samples
- Sample transport and material-transfer procedures are not standardized regionally
More countries are aligning with ICH-GCP. A 2019 regulatory roadmap called for harmonized biobank and sample-transfer frameworks across the region. National bodies such as the Saudi FDA, Jordan FDA, UAE DOH, and Egyptian MoH are each moving toward international benchmarks at their own pace. Feasibility planning depends on mapping each authority’s specific requirements early.
Common Challenges When Planning MENA Trials
Regulatory fragmentation across dozens of countries means a study plan built for one market rarely transfers cleanly to the next. Beyond regulatory variance, sponsors face:
- Site readiness gaps: infrastructure quality varies widely even within a single country
- Low public awareness: a 2016 Saudi study found 68.9% of respondents lacked basic clinical trial knowledge, and 82.7% had never participated in one
- Limited IRB familiarity: a 2019 follow-up study found only 26.8% of respondents knew what an IRB was
- Political and economic instability: sponsors must factor these risks into feasibility timelines early in select countries
None of these are dealbreakers. They're planning inputs. Sponsors who build in extra time for patient education and site vetting tend to avoid the worst delays.
How the Right Global CRO Partner Simplifies MENA Trial Planning
Running a MENA study well means pairing global regulatory know-how with people who actually understand local systems. That's the gap most sponsors underestimate: knowing SFDA's response clocks on paper is different from managing a live submission through it.
DRK Research Solutions maintains an operational presence in Dubai Silicon Oasis, part of a footprint spanning Europe, the Middle East, Asia, Africa, and the Americas. Since expanding into multi-regional clinical trials in 2018, DRK has built out end-to-end study start-up capabilities:
- Feasibility assessment and site identification
- Regulatory documentation and submission support
- Ethics-approval coordination
- Ongoing monitoring, project management, and data oversight
Site selection alone accounts for over half of typical clinical trial delays, which is why feasibility work upfront matters as much as the regulatory filing itself.
DRK's broader mission of expanding access to innovative therapies for underserved populations across low- and middle-income countries extends naturally to several MENA markets. Treatment-naive populations in these markets remain underrepresented in global trial data.
Frequently Asked Questions
How can I find clinical trials in the MENA region or near me?
Check ClinicalTrials.gov and the WHO's International Clinical Trials Registry Platform (ICTRP) for active studies by country. A regional CRO partner can also help identify upcoming trials matching specific therapeutic areas.
What are the biggest regulatory differences between MENA countries?
Most countries require sequential ethics committee approval before regulatory authority review, unlike parallel models used elsewhere. Language requirements also differ: Arabic is mandatory region-wide, with French added in North African countries.
Which MENA countries are most attractive for Phase II-III trials?
Saudi Arabia, the UAE, and Egypt currently lead the region, thanks to growing regulatory sophistication, hospital infrastructure, and large patient populations.
How long does clinical trial approval typically take in MENA?
Timelines vary significantly by country and phase. Saudi Arabia's SFDA, for example, publishes response clocks ranging from 10 working days for Phase IV to 60 working days for Phase I, though these apply only after a complete submission.
Is it cost-effective to run clinical trials in MENA compared to the US or Europe?
Yes. Many MENA markets offer lower operating costs and faster access to treatment-naive populations. No verified numerical cost or recruitment-speed benchmark against the US or Europe currently exists, so country-specific feasibility work is essential.
What role does a CRO play in MENA trial planning?
A CRO manages local regulatory submissions, site identification, ethics coordination, and ongoing compliance oversight. That support reduces the burden on sponsors navigating unfamiliar systems across multiple countries.
